Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency
Terminated
Nanfang Hospital of Southern Medical University
N/A
2008-02-01
The primary aim of the present study is to assess the safety of combined treatment of
benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced
renal insufficiency.
Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-12-01
The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and
hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets
following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed
conditions.
Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-11-01
The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and
hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets
following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting
conditions.
This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg
Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg
LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in
healthy adult volunteers under non-fasting conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
